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Cardiovascular disorders are known as one of the main health problems which are associated with
mortality worldwide. Myocardial ischemia (MI) is improper blood supply to myocardium which leads
from serious complications to life-threatening problems like AMI, atherosclerosis, hypertension, cardiac-
hypertrophy as well as diabetic associated complications as diabetic atherosclerosis/cardiomyopathy/
hypertension. Despite several efforts, the current therapeutic platforms are not related with signiﬁcant
results. Hence, it seems, developing novel therapies are required. In this regard, increasing evidences
indicated, curcumin (CRC) acts as cardioprotective agent. Given that CRC and its analogs exert their
cardioprotective effects via affecting on a variety of cardiovascular diseases-related mechanisms (i.e.,
Inﬂammation, and oxidative stress). Herein, for ﬁrst time, we have highlighted the protective impacts of
CRC against MI. This review might be a steppingstone for further investigation into the clinical impli-
cations of the CRC against MI. Furthermore, it pulls in light of a legitimate concern for scientiﬁc com-
munity, seeking novel techniques and characteristic dynamic biopharmaceuticals for use against
myocardial ischemia.
© 2019 Elsevier Masson SAS. All rights reserved.Contents
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Cardiovascular diseases are one of the main diseases which are
related to the mortality globally [1]. Cardiovascular diseases (CVDs)
are a class of diseases including heart or blood vessel-related dis-
orders. Coronary artery sicknesses incorporate angina, MI, stroke,
heart disappointment, hypertensive coronary illness, cardiomyop-
athy, and arrhythmias. CVDs are the main cause of the death in the
world. Hazard factors incorporate hypertension, smoking, hefti-
ness, terrible eating routine, blood cholesterol, and absence of ac-
tivity [2]. It is approximated that 90% of CVDs is preventable.
Hypertension results in 13% of CVD passing, though tobacco results
in 9%, diabetes and absence of exercise in around 6%, and heftiness
in 5% [3]. Because of speciﬁc meds, for example, anticancer medi-
cations like doxorubicin, unfriendly impacts lead to MI. Since old
occasions, therapeutic plants have been generally utilized in the
treatment of maladies. This data may ﬁll in as a groundwork in
recognizing novel prophylactic just as restorative investigations of
plant-determined standards.
Natural compounds are getting to be prominent globally and
broadly acknowledged as safe and effective therapeutics with fewer
adverse effects [4e10]. Natural compounds assume a signiﬁcant job
as wholesome enhancements and provide protection against car-
diovascular diseases [11,12]. Curcumin (CRC) is a polyphenolic from
turmeric (Curcuma longa) roots. It is chemically 1,7 - bis - (4 - hy-
droxy - 3 - methoxy phenyl) - hepta - 1,6 - diene - 3,5 - dione with
formula C21H20O6; and the pKa esteem is 8.54. CRC is for all intents
and purposes insoluble in water at an acidic and nonpartisan pH
however is dissolvable in methanol, ethanol, dimethylsulfoxide,
and acetone [13]. CRC, a functioning polyphenol of the brilliant zest
turmeric, is an exceptionally pleiotropic molecule with the possi-
bility to adjust the natural movement of various signaling mole-
cules [14]. CRC is used against different cancers (e.g., breast,
colorectal, head and neck, lung, pancreatic and different myeloma),
neurologic disorders (e.g., Alzheimer's, and Parkinson's diseases) ;
skin problems (i.e., psoriasis, vitiligo), inﬂammatory diseases: (i.e.,
H. Pylori infection, peptic ulcers, osteoarthritis, rheumatoid joint
pain, ulcerative colitis, uveitis), metabolic scatters such as diabetes,
obesity and hepatoprotection [15e17]. Ongoing investigations have
shown that CRC can target recently recognized signaling pathways
incorporating those related with microRNA, cancer stem cell and
autophagy [18,19]. Broad research from preclinical and clinical ex-
aminations has portrayed the molecular reason for the pharma-
ceutical employments of this polyphenol against malignancy,
pneumonic sicknesses, neurological maladies, liver diseases,metabolic diseases, immune system diseases, cardiovascular dis-
orders, and various other perpetual diseases [20,21]. Different in-
vestigations have shown the wellbeing and adequacy of CRC in
various animal models and have given a strong premise to assess-
ing its security and viability in people. Until this point, in excess of
65 human clinical preliminaries of CRC, which included in excess of
1000 patients, have been ﬁnished, and upwards of 35 clinical pre-
liminaries are in progress [22,23]. This review is therefore, focused
on the mechanistic insight of CRC in the treatment of MI.
1.1. Overview of CRC in cardiovascular disorders
CRC have been shown to possess cardioprotective effects. It is
not only helpful in decreasing the risk of cardiovascular disease
(CHD) by reduction in cholesterol absorption to decrease delivery of
cholesterol to the liver improving plasma lipid proﬁles and
reducing inﬂammation [24]. It can normalize blood lipid proﬁles
and boosting arterial structure and function. CRC is reported to
protect from aortic aneurysm, Doxorubcin induced cardiotoxicity,
myocarditis, heart attacks, thrombosis, cardiac ﬁbrosis; lowers
blood cholesterol and pressure; as well as reduces and cardiovas-
cular complications of diabetics such as diabetic cardiomyopathy,
MI and stroke [25].
MI leads to AMI, atherosclerosis, hypertension, cardiac hyper-
trophy as well as diabetic associated complications as diabetic
atherosclerosis/cardiomyopathy/hypertension. Behind these ef-
fects’ apoptosis, oxidative stress and inﬂammation are involved.
Furthermore, Structural integrity after ischemic injury also
disturbed which leads to arrhythmic effects and hypertension
[25,26].
2. Underlying mechanisms of CRC in myocardial ischemia
2.1. Oxidative stress
2.1.1. Acute myocardial infarction
CRC is a promising contender for counteractive action of IRI and
the related free radical started maladies due to its prevalent anti-
oxidant effects. Reactive oxidative species (ROS) directly injured the
cell membrane in the ischemic myocardium, causing cell death and
contractile failure resulting in acute MI. Dysfunctional mitochon-
drial Ca2þ channels and activation of ERK and JNK signaling path-
ways due to ROS formation causes cell death during IRI. This
activation participates in further ROS production and Ca2þ dysho-
meostasis [27]. CRC suppresses ROS hence ameliorates myocardial
Fig. 1. A scheme of CRC effects on oxidative stress-related mechanisms in the CVDs. The CRC mediated anti-inﬂammatory and antioxidant effects involving Nrf2, NF-kB, PPAR-g and
mitochondria. CRC caused overexpression of Superoxide dismutase (SOD), catalases (CAT), endothelial nitric oxide synthase (eNOS), Glutathione (GSH), Liver X receptor a (LXRa),
Peroxisome proliferator-activated receptor gamma (PPARg), ATP-binding cassette transporter A1 (ABCA1), and carveolin-1 for cardiac-protective effects. Similarly, it produced
downregulation of reactive oxidative species (ROS), Angiotensin II type 1 receptor (AT1R), Lipoxygenase (LOX), Thiobarbituric acid reactive substances (TBARS), Lactatedehy-
drogenase (LDH), Malondialdehyde (MDA), Mitochondrial hydrogen peroxide, Oxidized low-density lipoprotein (OxLDL), Niemann-Pick Cl-like 1 (NPC1L1), Angiotensin II (Ang II)
mediated reactive oxidative species, Nicotinamide adenine dinucleotide phosphate (NADPH) for various cardiac-protective effects.
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drial H2O2 and the leakage of LDH and MDA (Fig. 1) [28e30].
2.2. Atherosclerosis
2.2.1. Expanded ROS development and resulting oxidative
alterations in lipids and vessels and causes atherogenesis [31].
During myocardial IRI, ROS production mediated mitochondrial
dysfunction and hence play an important role in atherogenesis by
oxidizing LDL and plaque rupture by matrix metalloproteinases
activation [27]. CRC is valuable in bringing down LDL and raising
HDLwhile lessening lipid peroxidation by ROS scavenging [32]. CRC
included before anoxia or promptly preceding reoxygenation
showed surprising defensive impacts against anoxia-reoxygenation
by hindering lipoperoxidation [33]. Another investigation has
demonstrated that CRC essentially brings down LDL and expands
HDL in healthy patients [34]. CRC has appeared hostile to athero-
genic impact on apo E/LDLR-twofold knockout mice by shielding
LDL from oxidation and restrain platelet accumulation [35].
Decrease in the atherosclerotic injuries and diminished oxidized-
LDL-incited cholesterol was observed after CRC [36]. CRC (10mg)
directed twice day by day for 15 days essentially brings down
plasma ﬁbrinogen in atherosclerosis [37]. In high-fat eating
regimen hamsters, CRC essentially brought down the dimensions of
free unsaturated fat, cholesterol, triglyceride, and leptin; just as
diminished hepatic cholesterol and TG. CRC additionally improved
PON action and brought down lipid peroxidation [38]. CRCfundamentally diminishes dimensions of AST, ALT, LDL, CRP, ICAM-
1 and VCAM-1, yet essentially increment dimensions of NO and
HDL-C in HSF diet given to rodent [39]. The antioxidant role of CRC
also knows an important role for upgrading the cholesterol efﬂux
and diminishes cholesterol absorption. CRC upgraded cholesterol
efﬂux by expanding ABCA1, PPARg, LXRa articulation [40]. CRC,
display an enemy of atherosclerotic impact, which is intently con-
nected with an expansion in cholesterol efﬂux fundamentally by
expanding HO-1 articulation and initiation of the Nrf2 ARE
signaling pathway [41]. CRC diminishes cholesterol absorption in
the small digestive tract, brings down cholesterol and hinders early
atherosclerosis [42]. CRC, likewise can hinder cholesterol take-up
by restraining NPC1L1 outﬂow [43]. CRC represses ox - LDL–
incited cholesterols' addition in VSMCs through expanding caveolin
- 1 articulation by means of the restraint of SREBP -1 [36]. Fig. 2
illustrates the pathogenesis of atherosclerosis.
2.2.3. Hypertension
Hypertension is signiﬁcant risk factor for IHD which instigates
endothelial dysfunction, fuels the atherosclerotic procedure and it
adds to make the atherosclerotic plaque increasingly insecure. LVH,
which is the standard complexity of hypertension, advances an
abatement of ‘coronary hold’ and increments myocardial oxygen
request, both mechanisms adding to myocardial ischemia [44]. The
antioxidant effect by CRC promoting NO release for vasorelaxation
[45]. Ang II signiﬁcantly raised in the setting of hypertension and
myocardial dead tissue. Ang II transmitted its action by AT1R
Fig. 2. A scheme of acute myocardial injury pathogenesis. A variety processes are activated with release of cytokines and ROS with inﬁltration of circulating neutrophils and
monocytes leading to AMI. Simultaneously several remote sites are also activated (e.g. spleen, bone marrow) though signaling pathways that lead to the activation of the immune
system and injury. Subsequently, a reparative phase ensues predominantly mediated by monocytes and T-lymphocytes leading to tissue repair and recovery with over expression of
processes involved in extracellular matrix deposition and angiogenesis. Abbreviations: AMI: acute myocardial injury; ROS: reactive oxygen species; TLR: toll-like receptors; DAMPS:
damage associated molecular patterns; HSP: heat shock proteins; HMGB1: high mobility group box 1 protein; VCAM: vascular cell adhesion molecule; NLR: NOD-like receptor;
NLRP3: NOD-like receptor family pyrin domain containing 3; IL: interleukin; TNF: tumour necrosis factor; IFN: interferon; CX3CR1: CX3 chemokine receptor 1; miRNA: micro
ribonucleic acid; CRP: C reactive protein; SAA: serum amyloid A.
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decreasing AT1R-interceded vasoconstriction and thusly averts the
advancement of hypertension [47]. Ang II provides ROS in athero-
sclerosis which further results in vasoconstriction and increased
blood pressure. CRC weakens heart ﬁbrosis in SHR and represses
Ang II-initiated CTGF, ECM and PAI - 1 generation in CF [48]. CRC
constricts the improvement of hypertension in L-NAME-incited
hypertensive rats. CRC treatment smothers circulatory strain rise,diminishes vascular oppositionwith an expansion in eNOS and GSH
and decline of peroxidation [49].2.2.4. Cardiac hypertrophy
CRC restrains the activity of the AT1R and LOX-1, to suppress
hypertrophic markers and cardiomyocyte growth. CRC attenuates
Ang II-instigated ROS, upregulation of AT1R and LOX-1 expression
as well as expression of NADPH oxidase which inhibit
S. Ahmed et al. / European Journal of Medicinal Chemistry 183 (2019) 111658 5cardiomyocyte growth [50,51].
2.2.5. Diabetic atherosclerosis
CRC by diminishing the TG, expanded dimensions of adipo-
nectin in diabetes patients can lessen the danger of atherosclerosis
[52]. CRC analog L3 mitigates diabetic atherosclerosis by lessen
oxidative pressure, as a result causing NO increment, decline ROS
generation and LOX-1 articulation, and amend fatty atherosclerotic
degeneration [53]. In STZ-nicotinamide-actuated diabetic rodents,
THC, one of the dynamic metabolites of CRC decreased blood
glucose and critical increment of plasma insulin as well as
decreased TC, TG and LDL in diabetic rodents [54].
2.2.6. Diabetic cardiomyopathy
Introduction of high glucose in vascular endothelial cells builds
iNOS and eNOS dimensions, CRC may hinder iNOS and eNOS effect
to lessen NO, in this manner applying its anti-oxidation against
diabetic cardiomyopathy in rats [55]. Furthermore, CRC notably
diminishes the action of NADPH oxidase and the ROS generation in
LV, in STZ-instigated diabetic rodents to reduce cardiac hypertro-
phy [56,57]. CRC supplementation is shown to signiﬁcantly atten-
uate ABP in STZ - induced diabetes in rats [58].
2.3. Apoptosis
2.3.1. Acute myocardial infraction
Myocardial IRI results in myocardial dysfunction is followed by
myocyte apoptosis by activation of Caspase-3, Bcl - xL and Bcl - 2
expansion and suppress Bax, Bak, Bad and Bid), cytokines and ROS
generation, cell to cell interaction between inﬂammatory and
endothelial cells, mitochondrial Cyt c discharge and causes AMI
(Fig. 2) [59]. CRC can diminish infarct size and protect car-
diomyocytes against apoptosis-related cardiac diseases by acti-
vating PI3K, Akt, ERK1/2 and Bcl-2 expression; suppressing JNK,
p38 MAPK, Bax and caspase-3 which is mediated by the JAK-2 and
JAK2/STAT3 signaling pathway (Fig. 3) [60e62].
2.3.2. Atherosclerosis
CRC lessens apoptosis, VSMC calciﬁcation, probably by targeting
a sequence of cellular and molecular pathways including JNK/Bax
pathway [63]. CRC additionally diminishes cholesterol-actuated
multiplication of aortic rat VSMC by means of reestablishing
caveolin-1 articulation which prompts the concealment of ERK
signals and G1/S stage capture [64].
2.3.3. Cardiac hypertrophy
Cardiomyocyte apoptosis goes about cardiovascular hypertro-
phy which prompt heart failure. Directed nanotization indicated
higher heart bioavailability of CRC at a low portion of 5mg/kg bw
contrasted with free CRC at 35mg/kg bw. Also, CRC with peptide
treatment amid hypertrophy altogether improved cardiovascular
capacity by suppressing ANF, b-MHC, Bax, Cyt c; Caspase 3 and
Poly-ADP-ribose polymerase (PARP) articulation; while CRC in a lot
higher portion indicated minimal improvement amid bargained
heart work. Targeted CRC treatment essentially brought down p53
articulation and enactment in unhealthy myocardium by means of
repressed association of p53 with p300-HAT in this way restricting
cardiomyocytes' have to enter the recovery cycle amid hypertrophy
[65].
2.4. Inﬂammation
2.4.1. Acute myocardial infarction
CRC mitigates myocardial IRI by weakening inﬂammation. It
restrains the upregulation of IL-1,6,8, TNF-a, NF-kB and Egr-1following IRI in rabbit as well as reduction of infarct size (Fig. 4)
[66]. CRC treatment is additionally appeared to diminish infarct size
in cardiovascular IRI model through inactivation of TLR-2 [67]. CRC
treated rodents by inhibiting p300-HAT diminishes LV wall thick-
ness to protect heart from cardiac failure [68]. ACS is a term used to
depict a scope of conditions related with abrupt, decreased blood
stream to the heart, temperamental angina and MI. Inﬂammation
partakes in all phase of atherosclerosis extraordinarily plaque
rupture. Most cases of deadly MI came about because of thrombosis
primarily after atherosclerotic plaque break [69]. CRC have capacity
to lessen TC and LDL in ACS [70] and furthermore decline NF - kB,
AP - 1, IL - 1, 6, TNF - a, MMP - 9, CRP in aversion of ACS [69]. CRC
may assume a signiﬁcant defensive job in AS procedure by dimin-
ishing plasma ADMA level [71].
2.4.2. Atherosclerosis
Warmed palm oil has been appeared to build the dimension of
homocysteine a marker of atherosclerosis in low estrogen state.
CRC has mellow impacts against multiple times warmed palm oil
with elevated cholesterol diet in estrogen lacking ovariectomized
rodents [72]. Raised AST/ALT proportion is fundamentally con-
nected with expanded danger of creating CVD [73]. In rats sus-
tained an elevated cholesterol diet (HCD), CRC expanded serum
dimension of LDL-C, yet a diminished HDL-C. CRC additionally
diminished the protein exercises of AST and ALT [74]. Against
platelet exercises of CRC, it showed anti-thrombotic activity with
hindrance of platelet enactment [75,76]. CRC has been appeared to
display hostile to atherosclerotic activity through NF-kB suppres-
sion resulting reduction in the IL-1, 6 and TNF-a actuation. Also,
CRC has been accounted for to hinder COX-2, LOX, and iNOS exer-
cises that are linked with creating lipid mediators [77e79]. The
nutraceutical mix of aged red rice, berberine, and CRC decrease TC,
TG, LDL-C, oxLDL; TNF-a and CRP in subjects at low cardiovascular
hazard. The treatment was very much endured and none of the
patients ceased treatment because of unfriendly impacts. No in-
stances of myalgia or musculoskeletal framework issue were
watched [80]. CRC applies an antiatherosclerotic impact, which is
interceded by bringing down serum lipids and ox-LDL, along these
lines adjusting the proinﬂammatory cytokine levels and repressing
MMPs, assume a signiﬁcant job against atherosclerosis [81,82]. CRC
additionally down directs MAPK pathway through concealment of
TNF - a - stimulated ROS, JNK, p 38 MAPK and STAT-3 phosphory-
lation in endothelial cells [83].
CRC restrained oxLDL prompted NF - kB initiation and p 38
MAPK phosphorylation thus repress the statement of MMP - 9 in
oxLDL invigorated macrophages [84]. Furthermore, by smothering
MMP - 9 articulation through down regulation of NF - kB, CRC may
avert the relocation of HASMCs. CRC's potential role in avoidance of
atherosclerosis is additionally upheld through its inhibitory impact
on VSMCs migration by diminished ROS production, concealment
of MMP - 9 enactment and protein articulation through down
regulation of NF e kB [85]. CRC copolymer nanoparticle (Cur-NPs)
signiﬁcantly diminished atherosclerosis injury territories as
compared with free CRC by hindering the MMP - 2 and MMP - 9
[86]. CRC leads to lower MCP - 1 impacts by down-regulating the
MAPK and NF - kB pathway [87]. CRC stiﬂes MCP - 1 generation
initiated by ox-LDL and improves cholesterol efﬂux in macrophage
by means of smothering the JNK and NF-kB pathways [88]. CRC
restrained PMA-interceded actuation of ERK and NF-kB transcrip-
tional action which demonstrates its anti-inﬂammatory by
repressing the emissions of MCP-1 [89]. TLR4 has been accounted
for to assume a basic job in the pathogenesis of atherosclerosis.
TLR4 as an important focus to balance or hinder threatening mac-
rophages in atherosclerotic sores. CRC supplementation altogether
diminished TLR4 articulation and macrophage invasion in
Fig. 3. A scheme of CRC effects on apoptosis-related mechanisms involved in myocardial ischemia mediated disorders. The underlying mechanism of apoptosis by CRC in
myocardial ischemia mediated disorders involved multiple molecular targets including enzymes (such as COX-2, superoxide dismutase (SOD), transcription factors (such as b-
catenin, NF-kB, AP-1, peroxisome proliferator-activated receptor gamma (PPAR-g), and p53), ROS, Bcl-2 family members (such as Bak, Bcl-2, Bax, and Bcl-xL), BH3 proteins (such as
Bim, Bad, and Bid), protease enzymes (such as caspase 3, caspase 8), death receptors (such as death receptor 5 (DR5), Fas), and other important signaling pathways such as p53,
phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), JNK, and ER stress. CRC caused upregulation of protein kinases (Akt), PI3K¼Phosphoinositide 3-kinase (PI3K), B-cell
lymphoma 2 (BCL-2) and Extracellular signaleregulated kinases (ERK ½) while downregulation of c-Jun N-terminal kinases (JNK), Bcl-2-associated X protein (BAX), P38 mitogen-
activated protein kinases (P38MAPK), Caspase-3and Poly-ADP-ribose polymerase (PARP) in the treatment of acute myocardial infraction, atherosclerosis and cardiac hypertrophy.
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plasma IL - 1b, TNF - a, ICAM - 1 and VCAM - 1 articulation and NF -
kB activity. What's more, CRC treatment diminished the degree of
atherosclerotic sores and repressed atherosclerosis improvement.
In vitro, CRC hindered NF - kB initiation in macrophages and
diminished TLR4 articulation incited by lipopolysaccharides [90].
CRC signiﬁcantly diminished ox-LDL-incited IL - 1b, IL - 6 and TNF -
a. CRC up-directed ABCA1and CD36 in M1 macrophages by
expanded PPARg articulation. CRC may build the capacity of M1
macrophages to deal with destructive lipids, along these lines apply
an enemy of atherosclerotic impact [91].
CRC hinders foam cell development, regulates the polarization
and pliancy of macrophages for relieving the atherosclerosis injury,
through affecting the TLR4/MAPK/NF - kB pathways, avoid the
advancement of inﬂamed atherosclerosis injuries [92]. Hypoxia has
been demonstrated to take part in the progression of atheroscle-
rosis, while CRC can hinder HIF-1a incited apoptosis and irritationof macrophages by means of ERK signaling pathways [93].
CRC has been appeared to stiﬂe the enlistment of Egr-1 in
endothelial cell, ﬁbroblast and VSMCs [94]. LCN2 is the most
encouraging biomarkers of atherosclerosis also down regulated by
CRC [95]. The vascular antiproliferative impact of CRC is likewise
exhibited through the enlistment of HO articulation in VSMC [96].
VSMC relocation and collagen synthesis are likewise key occasions
associated with obsessive changes happening with atherosclerosis.
Development factors, for example, PDGF and ﬁbroblast develop-
ment factor, discharged amid vascular damage assumes a vital role
in directing these occasions. CRC displays powerful inhibitory
consequences for PDGF-prompted VSMC proliferation, relocation
and collagen synthesis. CRC repress PDGF-invigorated VSMC ca-
pacities after carotid artery injury. This inhibitory impact on
vascular redesigning is owing to the constriction of PDGF-
prompted enactment of PDGF-R, ERK 1 and 2 and PKB motioning
by CRC in VSMC [97]. The quickened atherosclerosis is additionally
Fig. 4. Anti-inﬂammatory effects of CRC against myocardial ischemia mediated disorders. The effects were produced through downregulation of C-reactive protein (CRP), Myocyte
enhancer factor-2 (MEF2), Matrix metallopeptidase 9 (MMP-9), Toll-like receptor (TLR), Monocyte chemoattractant protein-1 (MCP-1), Cyclooxygenase-2 (COX-2), vascular cell
adhesion molecule-1 (VCAM-1), Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumour necrosis factor e a (TNF-a), Early growth response protein-1 (Egr-1), Histone acetyltransferase
p300 (p300-HAT) and Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB).
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and diminished Tregs in the spleen. CRC also diminished Th2 and
expanded Treg cells to ameliorate atherosclerosis sores aggravation
[98].
2.4.3. Hypertension
The idiopathic pulmonary arterial hypertension progressively
creates an expanded vascular obstruction. The anti-inﬂammatory
impacts of CRC demonstrates a job for inactivation of NF-kB-
interceded irritation propose it for treatment of idiopathic pneu-
monic blood vessel hypertension [99].
2.4.4. Cardiac hypertrophy
MI or ischemic stroke also results to cardiac hypertrophy (LVH)
[100,101]. CRC treatment attenuates the Ang II-mediated NF-kB
activation to decrease cardiac hypertrophy [51]. CRC treatment
anticipates the weakening of systolic capacity with improves LV
diastolic capacity [102]. CRC expands NCX and eNOS articulation in
myocardium resulting improved LV ejection fraction and diastolic
capacity [103].
CRC hindered IL-6, 8, MCP-1 articulation in high glucose reﬁned
myocytes to protect from diabetic cardio myopathy [104]. Egr - 1,
TNF - a, and NF - kB have been ﬁrmly connected with the enlist-
ment of insulin opposition and CRC down directs their demeanor,
enactment or capacity, proposing their putative job in beating in-
sulin obstruction [38,55,105,106]. Diabetic cardiomyopathy even-
tually leads to heart failure [107]. CRC treatment prevents diabetes-
induced upregulation of p300-HAT and MEF2, suggesting a pro-
tective role in diabetic hypertrophy [108]. The novel CRC analogue
B06 improved diabetic myocardial damage by smothers IL - 6 and
TNF - a overexpression by means of hindering JNK/NF - kB path-
ways in diabetic rats [109]. The Egr-1 which directs the translation
of a few genes engaged with inﬂammation, differentiation, growthand development is additionally inhibited by CRC [94]. Together,
these discoveries show that CRC is a powerful medication applicant
against diabetic cardiomyopathy.
2.5. Structural integrity after ischemic injury
2.5.1. Maintain the intracellular integrity of cardiomyocytes
Upregulation of myocardial CTSD by CRC in MI protects against
heart failure [110]. CRC also expanding HSP-27 articulation to
facilitate cytoskeletal stabilization, thereby protecting the
myocardium from IRI [30].
The antiﬁbrosis action of CRC is due to decrease SIRT1 articu-
lation to attenuate collagen deposition [111]. Moreover, in Sprague -
Dawley rats, CRC inhibits ﬁbroblast differentiation and attenuates
collagen synthesis by TGF-b1/Smad signaling pathway to maintain
normal structure of ECM after MI [112]. ECM remodeling following
IR attenuated by CRC, suppressing MMP - 2, MMP -9 articulation
[28,113], collagen synthesis by suppressing ROS [114] and regulated
ANP, MYH7, procollagen I and III [115].
2.5.2. Antiarrhythmic effects
Cardiac ischemia resulting in disturbance of electrical conduc-
tivity with pro-arrythmic effects such as VT and remain a common
cause of sudden death in AMI and less restrained by pharmaco-
logical therapy [116]. CRC reduces IRI induced dysrhythmias such as
VPB, VT and VF by expanding Cx43 and targeting SERCA pump thus
promotes rhythmic contraction of myocytes [117e119]. CRC con-
tributes to anti-arrhythmic effects by inhibiting hERG Kþ channels
[120].
2.5.3. Antihypertensive effects
CRC restrains Ang II - instigated CTGF, PAI-1, and ECM creation in
CF, and lessens heart ﬁbrosis in SHRs, propose a conceivable novel
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brought about by hypertension [48]. Additionally, CRC inhibits
p300-HAT to attenuate cardiac hypertrophy [121e123]. It also im-
proves cardiac remodeling by reduced L V mass and dilatation with
attenuation of GSK-3, NFAT, PKB and ERK1/2, pERK, and p-cAMP-
dependent kinases [124].
3. Clinical status of CRC in myocardial ischemia
Few clinical trials have been accounted for indicating useful job
of CRC against myocardial ischemia. A 12week randomized placebo
controlled trial on 118 subjects demonstrated that CRC diminished
danger of creating acute CV occasions in type 2 diabetics muddled
by dyslipidemia [125]. Another randomized placebo-controlled
examination on 45 postmenopausal ladies uncovered that the
decrease in LV afterload and systolic blood pressure was at a more
prominent degree with the mix of continuance exercise alongside
CRC admission [126]. CRC 1 g, daily signiﬁcantly constricted TG,
after 4-week [127]. A randomized controlled trial on 87 subjects
with nonalcoholic fatty liver infections uncovered a critical decline
in TC, TG, HDL-C pursued by 1 g CRC 8weeks supplementation
[128]. Same results were seen with decreased serum leptin and
expanded adiponectin in diabetics [129]. Additionally, in other trial
CRC decline LDL, Apo B and improved Apo A1, HDL to keep from
atherosclerosis [34]. An examination on 121 patients was conveyed
to assess the impact of CRC (4 g/day) in AMI counteractive action
after coronary bypass grafting, indicated diminished 13% AMI with
brought down MDA [130]. CRC (1-week) treatment decreased the
dimension of atherosclerotic a1 -antitrypsin - LDL (AT - LDL)
complex, prompting the avoidance of atherosclerosis [131].
4. Overcoming to the CRC limitations: from analogs to
delivery systems
CRC gives security against MI through lessening oxidative
pressure, apoptosis, and inﬂammation. Through thesemechanisms,
AMI, atherosclerosis, hypertension, heart hypertrophy just as dia-
betic related myocardial ischemic complexities. It additionally
keeps up the intracellular uprightness of cardiomyocytes to di-
minishes ECM demonstrating and hostile to arrhythmic impacts in
a similar association. CRC is a for the most part perceived as pro-
tected GRAS compound and generally well-tolerated [25]. Poor
gastrointestinal assimilation, water insolubility and molecular un-
steadiness have shown the poor fundamental bioavailability of CRC
which neglects to clarify its powerful pharmacological impacts and
ruins its clinical applications [132]. Adjuvant co-organization
forestalls its fast metabolism whereas liposomes, micelles and
phospholipid ediﬁces, cellulosic subordinates altogether diminish
the hydrophobicity of CRC and increment the membrane perme-
ability [133,134]. Modiﬁcation of CRC speaks to another way to deal
with improve its bioavailability, stability, and therapeutic impacts,
for example, lessening the molecule diameter and lipids encapsu-
lation [135].
Additionally, appropriate drug combinations (celecoxib,
piperine and nebivolol) that may improve defensive impacts
against myocardial ischemia have all the earmarks of being a
promising road [136e138]. Improvement of progressively powerful
engineered CRC analogs, for example, CDF (3, 4-diﬂuor-
obenzylidene CRC) [139], dehydrozingerone [140] and drazino CRC
[141] upgrade bioavailability, biological activity, and stability.
Nano-encapsulation of CRC improved its solvency, bioavailability
and stability with better viability [142,143]. Hardly few clinic
studies have recognized the gainful role of CRC against myocardial
ischemia, which prompts an inadequate picture as a pharmaco-
logical agent. In this way, extensive clinical explorations are yetrequired to conclude the potential therapeutic of CRC, which may
help in the counteractive action and treatment of myocardial
ischemia and its related pathological conditions later.
5. Conclusion and future directions
Altogether, it has been observed that CRC is a very versatile and
potential therapeutic modality in the effective management of
cardiovascular complications. The different underling mechanisms
that account for the cardiovascular disorders such as oxidative
stress, apoptosis and inﬂammation are effectively addressed by CRC
at molecular level. While applying different formulation technol-
ogies and structural modiﬁcations, some of the core limitation in
CRC effects has already been rectiﬁed and thus, comprehensive
clinical studies could lead to effective drug discovery in the treat-
ment of cardiovascular disease.
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ABP Arterial blood pressure
ACS Acute coronary syndrome
ADMA Asymmetric dimethylarginine
ALT Alanine aminotransferase
AMI Acute myocardial infarction
ANF Atrial natriuretic factor
ANP Atrial natriuretic peptide
ARE Antioxidant response element
AST Aspartate aminotransferase
BAD Bcl-2/Bcl-X associated death domain protein
BAK Bcl-2 homologous antagonist - killer protein
Bcl-xL B-cell lymphoma-extra large
BID BH3 interacting domain death agonist
CF Cardiac ﬁbroblasts
CTGF Connective tissue growth factor
CTSD Cathepsin D
CVD Cardiovascular diseases
Cx43 Connexin 43
Cyt c Cytochrome c
ECM Extracellular matrix
GSK-3b Glycogen synthase kinases 3b
HASMCs Human aortic smooth muscle cells
HAT Histone acetyltransferase
HDL-C High-density lipoprotein cholesterol
hERG Human ether-a-go-go related gene
HIF-1a Hypoxia-inducible factor 1a
HO-1 Heme-oxygenase-1
HSP-27 Heat shock protein
ICAM-1 Intercellular adhesion molecule-1
IHD Ischemic heart disease
IRI Ischemiaereperfusion injury
JAK-2 Janus kinase 2
LCN2 Lipocalin-2
LDL Low-density lipoprotein
LDL-C low-density lipoprotein cholesterol
L-NAME Nu-nitro-L-arginine methyl ester
LOX-1 Lectin-like oxidized low-density lipoprotein receptor-1
LVH Left ventricular hypertrophy
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MYH7 Myosin heavy chain 7
NCX Naþ/Ca2þ exchanger
NFAT Nuclear factor of activated T-cells
NOS Nitric oxide synthase
Nrf2 Nuclear factor (erythroid-derived 2)-like 2
PAI-1 Plasminogen activator inhibitor
PDGF-R Platelet-derived growth factor receptor
pERK Phosphorylated form of extracellular receptor kinase
PkB Protein kinase B
PMA Phorbol myristate acetate
PON Paraoxonase
SERCA Sarcoendoplasmic reticulum calcium transport ATPase
SHR Spontaneously hypertensive rats
SIRT1 Sirtuin 1
SREBP-1 Sterol response element-binding protein-1
STAT-3 Signal transducer and activator of transcription 3
b-MHC b-myosin heavy chainReferences
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